Recombinant Human ARHI Protein (Fc Tag)

Name: Recombinant Human ARHI Protein (Fc Tag)
Brand: Beta LifeScience
SKU: BLPSN-0257
Availability: InStock

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	Fc
Host Species	Human
Accession	O95661
Synonym	ARHI, DIRAS3, NOEY2, RHOI
Background	ARHI, also known as DIRAS3, belongs to the small GTPase superfamily, Di-Ras family. ARHI gene is a novel tumor suppressor gene located on chromosome 1p31. Downregulation of ARHI expression has been detected in many types of cancer. ARHI is expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers. As a suppressor, ARHI is not only an important factor in the pathogenesis of gastric cancer, but also a potential factor for tumor aggravation. ARHI expression in gastric cancer can be employed to indicate favorable prognosis for the disease.
Description	A DNA sequence encoding the human DIRAS3 (O95661) (Met1-Lys225) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Source	HEK293
Predicted N Terminal	Asp
AA Sequence	Met1-Lys225
Molecular Weight	The recombinant human DIRAS3/mFc comprises 461 a.a. and has a predicted molecular mass of 52.1 kDa. The apparent molecular mass of the monomer is approximately 62 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Purity	>85% as determined by SDS-PAGE
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Please contact us for detailed information
Formulation	Lyophilized from sterile PBS, pH 7.4..
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Subcellular Location	Cell membrane; Lipid-anchor; Cytoplasmic side.
Protein Families	Small GTPase superfamily, Di-Ras family
Database References	HGNC: 687 OMIM: 605193 KEGG: hsa:9077 STRING: 9606.ENSP00000360020 UniGene: Hs.194695
Tissue Specificity	Expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers.

Gene Functions References

Low DIRAS3 expression is associated with metastasis in gastric cancer. PMID: 30043279
lncRNA GAS5 functions as a competing endogenous RNA for miR-221 to suppress cell growth and EMT in osteosarcoma by regulating the miR-221/ARHI pathway. PMID: 28519068
DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF. PMID: 27368419
We demonstrate that DIRAS3 knock-down (KD) in adipose stromal/progenitor cells (ASCs) induces activation of Akt-mTOR signaling and proliferation arrest. DIRAS3 KD ASCs lose the potential to form colonies and are negative for Ki-67. Moreover, silencing of DIRAS3 results in a premature senescence phenotype. PMID: 28316325
ARHI-mediated up-regulation of glycolysis and glutaminolysis was found to be autophagy-dependent and inhibition of these metabolic pathways resulted in decreased cell viability. PMID: 27784287
The overexpression of ARHI promotes colon cancer SW480 cell apoptosis by inhibiting the level of Akt. PMID: 27774944
Transcriptional, but not post-transcriptional, silencing of GNG12-AS1 causes concomitant upregulation of DIRAS3, indicating a function in transcriptional interference. PMID: 26832224
ARHI mRNA and protein expression is markedly decreased in osteosarcoma MG-63 cells lines. Overexpression of ARHI inhibits cell viability and proliferation. PMID: 26165148
ARHI-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. PMID: 26247722
EZH2-''induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in epithelial ovarian cancer PMID: 25077680
ARHI competes with RanGTPase and interacts with importin beta via basic-acidic patch interaction, which leads to inhibition of STAT3 translocation. PMID: 25499977
Letter: ARHI suppresses pancreatic cancer by regulating ERK 1/2 signaling. PMID: 25675421
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3. PMID: 25193278
suggest that DIRAS3 not only regulates the autophagosome initiation complex, but induces autophagy in dormant, nutrient-deprived ovarian cancer cells that remain after conventional chemotherapy, facilitating their survival PMID: 24879154
ARHI is required for autophagy-meditated cancer cell arrest and ARHI inhibits signaling through PI3K/AKT and Ras/MAP by enhancing internalization and degradation of the epidermal growth factor receptor. PMID: 24769729
The silence of ARHI expression in vitro seems to accelerate the malignant transformation of healthy ovarian cells by restraining apoptosis and autophagy. PMID: 24476894
ARHI acts as a tumor suppressor gene in MDA-MB-231 cells and, although trichostatin A+5-aza-2'-deoxycytidine can block the cells at different cell cycle phase, the antitumor effect is ARHI-dependent. PMID: 24676336
Loss of ARHI expression is associated with glioma. PMID: 24458808
ARHI acts as a tumor suppressor by downregulating the NFkappaB signaling pathway, which results in the inhibition of cell proliferation, apoptosis and the cell cycle in the pancreatic tumor PANC-1 cell line PMID: 23447002
overexpression of ARHI gene might be associated with the inhibition of lung cancer cell growth, proliferation and invasion, and the promotion of apoptosis. PMID: 23247805
Results indicate that the aplysia ras homolog member I (ARHI) 3'UTR was a direct target of miR-221 in breast cancer MCF-7 cells. PMID: 23801152
acetylated STAT3 bound to the ARHI promoter and recruited DNA methyltransferase 1 for genetic modification. PMID: 23604529
Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA. PMID: 23871723
Expression of JMJD2A in infiltrating duct carcinoma is higher than in fibroadenoma, and is associated with ARHI, p53 and ER PMID: 23678541
DiRas3 interacts with C-RAF and downregulates MEK1 activity to restrict cell migration. PMID: 23157514
ARHI expression is present in the endometrium and up-regulated in ectopic endometrium, whereas in the ectopic endometrium of patients with malignant endometriosis its expression is often negative. PMID: 21602127
ARHI expression is downregulated in human gastric cancer and it may be a novel tumor suppressive target for gastric cancer therapy. PMID: 22497484
The consequence of complex formation is a DiRas3-mediated recruitment and anchorage of C-RAF to components of the membrane skeleton, suppression of C-RAF/B-RAF heterodimerization, and inhibition of C-RAF kinase activity. PMID: 22605333
downregulation of ARHI may play an important role both in the pathogenesis and aggravation of gastric cancer. ARHI gene CpG island methylation is a potential molecular basis of its downregulation. PMID: 22427032
The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples PMID: 22117988
ARHI has a critical and previously uncharacterized role in the regulation of ovarian cancer cell migration. PMID: 21643014
ARHI has pro-apoptotic effects on HCC cells, which is associated with the inactivation of both Akt and NF-kappaB survival pathways. PMID: 21933150
Data show that ARHI re-expression induces autophagic cell death in breast cancer cells and enhances the inhibitory effects of paclitaxel by promoting autophagy, apoptosis, and G2/M cell cycle arrest. PMID: 21244707
These data highlighted an important role for ARHI in controlling hepatocellular carcinoma growth and angiogenesis. PMID: 21093415
DIRAS3 gene is imprinted, with monoallelic expression from the paternal allele. PMID: 9874798
Data show that ARHI could compete for Ran-importin binding and induce disruption of importin-binding to cargo proteins, including STAT3. PMID: 19435463
A link between NOEY2 loss expression and the spreading mechanism of breast cancer may possibly exist. PMID: 12485503
ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers PMID: 12771940
Hypermethylation of CpG island II in the promoter region of ARHI is associated with the complete loss of ARHI expression in breast cancer cells. PMID: 12874023
ARHI may have a role in development and progression of ductal breast carcinoma in situ PMID: 14506155
Association between STAT3 and ARHI as well as the functional inhibition of STAT3 transcriptional activity by ARHI suggests a novel mechanism through which a putative tumor suppressor gene can inhibit STAT3 activity in breast and ovarian cancers. PMID: 16061651
Down-regulation of ARHI gene is associated with breast cancer PMID: 16158053
Down-regulation of ARHI due to loss of heterozygosity and promoter methylation is associated with ovarian cancers PMID: 18286529
DIRAS3 is a novel, prognostically relevant candidate gene that is frequently methylated and silenced in oligodendroglial tumors with 1p deletion. PMID: 18302158
provide evidences that ARHI downregulated in HCCs could play a role in liver cancer via acting as a tumor suppressor gene, which mainly was triggered by the epigenetic events in HCC specimens PMID: 18612997
ARHI can induce autophagic cell death, but can also promote tumor dormancy in the presence of factors that promote survival in the cancer microenvironment. PMID: 19033662
The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis. PMID: 19482475
ARHI represents a modulator of cancer cell proliferation and may play an important role in the development of pancreatic cancer. PMID: 19639215
Loss of heterozygosity at 1p31 (including ARHI) did not correlate with the mitotic activity index nor provide prognostic information. PMID: 19759414

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.